A year after the Biosecure Act was introduced, WuXi AppTec’s US revenue growth continued to drop significantly, and the ...

With the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the brighter side for 2025. | With the fate ...

Going forward, we forecast WuXi's revenue growth to ... WuXi plans to fund its capacity expansion primarily with its own capital. We assign a narrow moat rating to WuXi Biologics due to its ...

Based on data reported through the CDP 2024 Assessment Questionnaire, WuXi Biologics achieved a score of "A" for Water Security, standing out among over 25,000 companies evaluated.

WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins and plasmid DNA (pDNA). The worldwide market for microbial-derived products ...

Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development ...

WUXI, China, Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it ...